Bayer extends clinical development program for finerenone with Phase III study in patients with non-diabetic chronic kidney disease
The Pharma Data
SEPTEMBER 29, 2021
In 2017, an alarming 1.2 to enhance outcomes, new treatments which will target kidney-specific disease mechanisms are highly desired,” said Hiddo L. Christian Rommel, Member of the chief Committee of Bayer AG’s Pharmaceutical Division and Head of Research and Development.
Let's personalize your content